Gara Jalqabaatti › Limfomaa T-Selii › New York

Qorannoo klinikaalii Limfomaa T-Selii New York keessatti

Qorannoo 15 Limfomaa T-Selii f New York keessatti hirmaatuu jiru.

Magaalota New York keessatti

Takkalaa qorannoo (Ingiliffa)

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Columbia University, New York

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT04234048

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
fi 5 dabalataa

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04803201

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medicine, New York

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06561048

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Memorial Sloan Kettering Cancer Center, New York

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT04752826

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

University of Rochester, Rochester

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06724237

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center, New York
fi 1 dabalataa

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT05010005

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Rochester Skin Lymphoma Medical Group. PLLC, Rochester

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06854653

CD4CAR for CD4+ Leukemia and Lymphoma

Albert Einstein Health Network, New York

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 12 fi ol · Saalaa hunda · Haaromfame 24-Wax-2026 · NCT03829540

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Memorial Sloan Kettering, New York

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Wax-2026 · NCT05463263

A Registry for People With T-cell Lymphoma

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
Memorial Sloan Kettering Westchester (All protocol activities), Harrison
Weill Cornell Medical Center (Data Collection Only), New York
fi 2 dabalataa

Namoota walitti qabaa jiraQorannoo ilaalaa

Umuriin hundi · Saalaa hunda · Haaromfame 20-Cam-2026 · NCT05978141

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Icahn School of Medicine at Mount Sinai, New York

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Elb-2026 · NCT05996185

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

Columbia University Irving Medical Center, New York

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Sad-2025 · NCT06420089

Tissue Repository: CTCL Collection Protocol

Columbia University Irving Medical Center, New York

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Sad-2025 · NCT02840747

MB-105 in Patients With CD5 Positive T-cell Lymphoma

Memorial Sloan Kettering Cancer Center, New York

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Onk-2025 · NCT06534060

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Children's Hospital New York-Presbyterian, New York
Memorial Sloan Kettering Cancer Center, New York

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 1 hanga 21 · Saalaa hunda · Haaromfame 06-Mud-2024 · NCT05476770

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.